Johnson & Johnson will acquire robotic startup Auris Health for $3.4bn in cash, plus milestones payments of up to $2.4bn. Auris developed the FDA-cleared Monarch platform, which is expected to rival Intuitive Surgical's robotic-assisted bronchoscope device, Ion, awaiting FDA clearance.
Johnson & Johnson announced today it will acquire robotic startup Auris Health Inc. for $3.4bn in cash, plus milestones up to $2.4bn.
The companies have an existing partnership dating back to May 2018 to integrate J&J's Neuwave microwave ablation technology into Auris' robotic Monarch platform.
The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.
An interactive look at medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.
The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.
Health tech is at the forefront of the women's health sector, securing 38% of venture capital in 2024. However, panelists at the Anglonordic Life Science Conference held 3 April asserted that a successful therapeutic breakthrough is key to gaining investor confidence and accelerating venture capital.
The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.
A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.
